Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › EloraTZP phase 2b (obesity + T2D)

EloraTZP phase 2b (obesity + T2D)

EloraTZP, Eloralintide, Tirzepatide · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
EloraTZP, Eloralintide, Tirzepatide
Population
t2d
Phase
2
Duration
48 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
EloraTZP 3/5 mgt2d48—−13.2 % vs −3.0 %
Δ −10.2 pp
—−2.2 vs −0.3——————press release
EloraTZP 6/5 mgt2d48—−19.4 % vs −3.0 %
Δ −16.4 pp
—−2.7 vs −0.3——————press release
EloraTZP 6/10 mgt2d48—−19.9 % vs −3.0 %
Δ −16.9 pp
—−2.6 vs −0.3——————press release
EloraTZP 9/15 mgt2d48—−23.3 % vs −3.0 %
Δ −20.3 pp
—−2.9 vs −0.3——————press release
eloralintide 3 mgt2d48—−8.2 % vs −3.0 %
Δ −5.2 pp
—−1.1 vs −0.3——————press release
eloralintide 6 mgt2d48—−12.3 % vs −3.0 %
Δ −9.3 pp
—−1.4 vs −0.3——————press release
eloralintide 9 mgt2d48—−11.1 % vs −3.0 %
Δ −8.1 pp
—−1.3 vs −0.3——————press release
tirzepatide 15 mgt2d48—−14.8 % vs −3.0 %
Δ −11.8 pp
—−2.4 vs −0.32.9 vs 16.7—————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (9)
  • EloraTZP 3/5 mg · weight_eff · press release table
    Elora 3 mg + TZP 5 mg -13.2
  • EloraTZP 6/5 mg · weight_eff · press release table
    Elora 6 mg + TZP 5 mg -19.4
  • EloraTZP 6/10 mg · weight_eff · press release table
    Elora 6 mg + TZP 10 mg -19.9
  • EloraTZP 9/15 mg · weight_eff · press release table
    Elora 9 mg + TZP 15 mg -23.3
  • eloralintide 3 mg · weight_eff · press release table
    Elora 3 mg -8.2 %
  • eloralintide 6 mg · weight_eff · press release table
    Elora 6 mg -12.3 %
  • eloralintide 9 mg · weight_eff · press release table
    Elora 9 mg -11.1 %
  • tirzepatide 15 mg · weight_eff · press release
    tirzepatide 15 mg reduced body weight by an average of 34.4 lbs (14.8%
  • tirzepatide 15 mg · ae_dc · press release, safety paragraph
    Treatment discontinuation rates due to adverse events were 10.8% to 27.0% with EloraTZP, 0% to 10.8% with eloralintide, 2.9% with tirzepatide and 16.7% with placebo.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: EloraTZP phase 2b (obesity + T2D). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/eloratzp-phase-2b/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.